FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wieslawa Dragowska

Research Profile

Living Beings

Mouse

Chemicals & Drugs

Disorders

Breast Neoplasms

Procedures

Anatomy

Physiology

Phenomena

Co-author Network

Publications

TOP 3
Wieslawa H Dragowska; Yannick Franssen; Karen A Gelmon; Anita I Kapanen; Guido J J Kierkels; Dana Masin; Andrew I Minchinton; Mohammed A Qadir; Sherry A Weppler; Ling Yan Wong; Jennifer H E Baker; Marcel B Bally
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
J Kalra; B W Sutherland; A L Stratford; Wieslawa H Dragowska; Karen Gelmon; Shoukat Dedhar; Sandra E Dunn; Marcel B Bally
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.
Jennifer H E Baker; Jeffrey Lam; Alaistair H Kyle; Jonathan Sy; Thomas Oliver; Steven J Co; Wieslawa H Dragowska; Euan Ramsay; Malathi Anantha; Thomas J Ruth; Michael J Adam; Andrew Yung; Piotr Kozlowski; Andrew I Minchinton; Sylvia S W Ng; Marcel B Bally; Donald T T Yapp
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wieslawa Dragowska (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Wieslawa H Dragowska; Yannick Franssen; Karen A Gelmon; Anita I Kapanen; Guido J J Kierkels; Dana Masin; Andrew I Minchinton; Mohammed A Qadir; Sherry A Weppler; Ling Yan Wong; Jennifer H E Baker; Marcel B Bally
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
BMC cancer 2011;11():420.
2010: J Kalra; B W Sutherland; A L Stratford; Wieslawa H Dragowska; Karen Gelmon; Shoukat Dedhar; Sandra E Dunn; Marcel B Bally
Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.
Oncogene 2010;29(48):6343-56.
2008: Jennifer H E Baker; Jeffrey Lam; Alaistair H Kyle; Jonathan Sy; Thomas Oliver; Steven J Co; Wieslawa H Dragowska; Euan Ramsay; Malathi Anantha; Thomas J Ruth; Michael J Adam; Andrew Yung; Piotr Kozlowski; Andrew I Minchinton; Sylvia S W Ng; Marcel B Bally; Donald T T Yapp
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7260-71.
2008: Lincoln A Edwards; Janet Woo; Lynsey A Huxham; Maite Verreault; Wieslawa H Dragowska; Gigi Chiu; Ashish Rajput; Alastair H Kyle; Jessica Kalra; Donald T T Yapp; Hong Yan; Andrew I Minchinton; David Huntsman; Tim Daynard; Dawn Waterhouse; B Thiessen; Shoukat Dedhar; Marcel B Bally
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).
Molecular cancer therapeutics 2008;7(1):59-70.
2007: Wieslawa H Dragowska; Maite Verreault; Donald T T Yapp; Corinna Warburton; Lincoln Edwards; Euan C Ramsay; Lynsey A Huxham; Andrew I Minchinton; Karen Gelmon; Marcel B Bally
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Breast cancer research and treatment 2007;106(3):319-31.
2007: Donald T T Yapp; Janet Woo; Aileen Kartono; Jonathan Sy; Thomas Oliver; Kirsten Skov; Cameron J Koch; Hans Adomat; Wieslawa H Dragowska; Ladan Fazli; Ladan Fadzli; Thomas J Ruth; Michael J Adam; David Green; Martin Gleave
Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography.
BJU international 2007;99(5):1154-60.
2007: Gigi Chiu; Lincoln A Edwards; Anita I Kapanen; Melina M Malinen; Wieslawa H Dragowska; Corinna Warburton; Ghania Chikh; Karen Y Y Fang; Sophia Tan; Jonathan Sy; Catherine Tucker; Dawn Waterhouse; Richard J Klasa; Marcel B Bally
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.
Molecular cancer therapeutics 2007;6(3):844-55.
2007: Murray S Webb; Sharon A Johnstone; Tara J Morris; Allison Kennedy; Ryan Gallagher; Natashia Harasym; Troy O Harasym; Clifford R Shew; Paul G Tardi; Wieslawa H Dragowska; Lawrence D Mayer; Marcel B Bally
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2007;65(3):289-99.
2006: Dawn Waterhouse; Karen Gelmon; Richard J Klasa; Kim Chi; D Huntsman; Euan Ramsay; Ellen K Wasan; L Edwards; C Tucker; Jason Zastre; Y Z Wang; Y Z Zhang; Donald T T Yapp; Wieslawa H Dragowska; S Dunn; Shoukat Dedhar; Marcel B Bally
Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.
Current cancer drug targets 2006;6(6):455-89.
2006: Lincoln A Edwards; Maite Verreault; Brian Thiessen; Wieslawa H Dragowska; Yanping Hu; Juliana H F Yeung; Shoukat Dedhar; Marcel B Bally
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.
Molecular cancer therapeutics 2006;5(3):645-54.
2005: Euan C Ramsay; Nancy Dos Santos; Wieslawa H Dragowska; Janessa J Laskin; Marcel B Bally
The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.
Current drug delivery 2005;2(4):341-51.
2005: Lincoln A Edwards; B Thiessen; Wieslawa H Dragowska; Tim Daynard; Marcel B Bally; Shoukat Dedhar
Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
Oncogene 2005;24(22):3596-605.
2004: Kirsten Skov; Hans Adomat; Mary Bowden; Wieslawa H Dragowska; Martin Gleave; Cameron J Koch; Janet Woo; Donald T T Yapp
Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages.
Radiation research 2004;162(5):547-53.
2004: Wieslawa H Dragowska; Corinna Warburton; Donald T T Yapp; Andrew I Minchinton; Yanping Hu; Dawn Waterhouse; Karen Gelmon; Kirsten Skov; Janet Woo; Dana Masin; Lynsey A Huxham; Alastair H Kyle; Marcel B Bally
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Molecular cancer research : MCR 2004;2(11):606-19.
2004: Corinna Warburton; Wieslawa H Dragowska; Karen Gelmon; Stephen Chia; Hong Yan; Dana Masin; Tetyana Denyssevych; Anne E Wallis; Marcel B Bally
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2512-24.
2004: Dawn Waterhouse; Wieslawa H Dragowska; Karen Gelmon; Lawrence D Mayer; Marcel B Bally
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.
Cancer biology & therapy 2004;3(2):197-204.
2003: Ming-wan Su; Irene Dorocicz; Wieslawa H Dragowska; Vincent Ho; Gang Li; Nicholas J Voss; Randy D Gascoyne; Youwen Zhou
Aberrant expression of T-plastin in Sezary cells.
Cancer research 2003;63(21):7122-7.
2003: Wai Ming Li; Wieslawa H Dragowska; Marcel B Bally; Marie-Paule Schutze-Redelmeier
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
Vaccine 2003;21(23):3319-29.
2003: Yanping Hu; Marcel B Bally; Wieslawa H Dragowska; Lawrence Mayer
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
Molecular cancer therapeutics 2003;2(7):641-9.
2001: Yanping Hu; Wieslawa H Dragowska; Anne E Wallis; V Duronio; L Mayer
Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
Breast cancer research and treatment 2001;70(1):11-20.
2001: M Wong; S Kong; Wieslawa H Dragowska; Marcel B Bally
Oxazole yellow homodimer YOYO-1-labeled DNA: a fluorescent complex that can be used to assess structural changes in DNA following formation and cellular delivery of cationic lipid DNA complexes.
Biochimica et biophysica acta 2001;1527(1-2):61-72.
2000: K C Chi; Anne E Wallis; C H Lee; D L De Menezes; Jason R Sartor; Wieslawa H Dragowska; Lawrence D Mayer
Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
Breast cancer research and treatment 2000;63(3):199-212.
2000: Wieslawa H Dragowska; Daniel E Lopes de Menezes; Jason R Sartor; Lawrence D Mayer
Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis.
Cytometry 2000;40(4):346-52.